MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approv ...

Despite a series of positive operational updates, BioNTech's stock price remains anchored near its yearly lows. The company ...

The winter holidays can turn deadly as research shows that more people die from heart attacks during the last week of ...

The VA is accelerating a systemwide rollout of its new electronic health records platform, with full deployment at all ...

The VA is accelerating a systemwide rollout of its new electronic health records platform, with full deployment at all medical sites by 2031, according to the contractor handling the project. In 2026, ...

A multidisciplinary team integrated clinical need, cancer biology, and microfluidic bioengineering to advance ...

The FDA has qualified AI-Based Histologic Measurement of MASH, or AIM-MASH AI Assist — the first AI drug development tool — ...

Flow is a transcranial direct current stimulation device that delivers low-intensity direct electrical current to specific areas of the brain through electrodes that are placed on the scalp.

Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

Discover how quality control charts help track product standards, pinpoint issues, and ensure processes meet specifications with this essential tool for quality assurance.